{
  "pmcid": "9857635",
  "sha256": "86fe889c836fd03ac51dd5fe95aedabeeba56c019e403a30a794a2bf8b0ce7b8",
  "timestamp_utc": "2025-11-09T16:22:41.366944+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 14.819527522935779,
    "reading_ease": 17.93516284403674,
    "word_count": 327
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "multicenter, randomized, double-blind, placebo-controlled trial"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "multicenter, randomized, double-blind, placebo-controlled trial took place at 23 sites in Germany and Canada from January 2015 to January 2021"
      },
      "Participants": {
        "score": 2,
        "evidence": "Adult cardiac surgery patients with a European System for Cardiac Operative Risk Evaluation II score–predicted mortality of 5% or more or planned combined surgical procedures were randomized."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Patients were randomly assigned (1:1) by a web-based system to receive either perioperative intravenous high-dose selenium supplementation of 2000 μg/L of sodium selenite prior to cardiopulmonary bypass, 2000 μg/L immediately postoperatively, and 1000 μg/L each day in intensive care for a maximum of 10 days or placebo."
      },
      "Objective": {
        "score": 1,
        "evidence": "To assess the ability of high-dose intravenous sodium selenite treatment to reduce postoperative organ dysfunction and mortality in cardiac surgery patients."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary end point was a composite of the numbers of days alive and free from organ dysfunction during the first 30 days following cardiac surgery."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Patients were randomly assigned (1:1) by a web-based system"
      },
      "Blinding": {
        "score": 3,
        "evidence": "multicenter, randomized, double-blind, placebo-controlled trial"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 1416 adult cardiac surgery patients were analyzed"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "A total of 1416 adult cardiac surgery patients were analyzed"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Selenium did not increase the number of persistent organ dysfunction–free and alive days over the first 30 postoperative days (median [IQR], 29 [28-30] vs 29 [28-30]; P = .45). The 30-day mortality rates were 4.2% in the selenium and 5.0% in the placebo group (odds ratio, 0.82; 95% CI, 0.50-1.36; P = .44)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Safety outcomes did not differ between the groups."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "ClinicalTrials.gov Identifier: NCT02002247"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 22,
    "max_score": 25
  }
}